Skip to main content
The innovative ME17 melanoma trial has opened to enrollment

The innovative ME17 melanoma trial has opened to enrollment

One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.

More >>
 
myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

The myeloMATCH North American platform study is now open in Canada and comprises a series of clinical trials to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

More >>
 
The new MAC30 trial compares two treatments for early-stage breast cancer in premenopausal women

The new MAC30 trial compares two treatments for early-stage breast cancer in premenopausal women

MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence.

More >>
 
CCTG CO32 rectal cancer trial testing chemotherapy with radiotherapy

Recently activated, the CCTG CO32 rectal cancer trial testing chemotherapy with radiotherapy

The CCTG CO32 clinical trial testing chemotherapy alone versus chemotherapy plus radiotherapy prior to limited surgery for early rectal cancer has initiate in Canada.

More >>
 

Planned trials

ALC9

Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)

CE10

VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma

CO33

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial

HN14

Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC

MD1

CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)

More >>

ME18

Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

SC31

Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)

SR8

NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)

MA42

No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)

Recently activated

BR38

Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

More >>

HE2

STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)

More >>

PR26

Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)

More >>

SKC1

Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

More >>
Patient Representative: Lesley Beaton

Welcome to patient representative Lesley Beaton

We are pleased to welcome Lesley Beaton as the new patient representative supporting the Gastrointestinal Disease Site Committee.

Lesley lives in Vancouver, BC, and brings both scientific and personal experience to her role. She spent more than three decades working in microbiology and regulatory compliance with Health Canada, gaining a scientific perspective on healthcare systems. 

More >>
 
Patient Representative: Catherine Caule

Welcome to patient representative Catherine Caule

Please join us in welcoming Catherine Caule, who is the new patient representative supporting the Hematology Disease Site Committee.

Catherine is a long-time health advocate based in Ottawa, Ontario, and a 25-year member of the Lymphoma Support Group of Ottawa. After being diagnosed with advanced Hodgkin Lymphoma and participating in a clinical trial for relapsed disease, she became a passionate voice for patient-centered care and equitable access.

More >>
 
workshop on patient engagement in clinical trials

Spring Meeting 2025 - Engaging Patient Representatives in CCTG Clinical Trials

If you are attending the CCTG Spring Meeting #CCTG2025 don't forget to drop by the open workshop and education session on engaging patient representatives in CCTG clinical trials. This accredited workshop takes place on Friday April 25, 10:30-12pm in the Seymour room at the Chelsea Hotel.

More >>
 
The innovative ME17 melanoma trial has opened to enrollment

The innovative ME17 melanoma trial has opened to enrollment

One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.

More >>